Retapamulin
Brand names: Altabax · Active ingredient: Retapamulin
In short: ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolate
What is Retapamulin used for?
ALTABAX is indicated for use in adults and pediatric patients
aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in
pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates
only) or Streptococcus pyogenes
.
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of ALTABAX and other antibacterial drugs, ALTABAX should
Retapamulin dosage
A thin layer of ALTABAX should be applied to the affected area (up to 100
cm2 in total area in adults or 2% total body surface area
in pediatric patients aged 9 months or older) twice daily for 5 days. The
treated area may be covered with a sterile bandage or gauze dressing if desired
.
How to take Retapamulin — instructions & advice from the label
Patients using ALTABAX and/or their guardians should receive the
following information and instructions: Use ALTABAX as directed by the
healthcare practitioner. As with any topical medication, patients and caregivers
should wash their hands after application if the hands are not the area for
treatment.
ALTABAX is for external use only. Do not swallow ALTABAX or use it in the
eyes, on the mouth or lips, inside the nose, or inside the female genital area.
The treated area may be covered by a sterile bandage or gauze dressing, if
desired. This may also be helpful for infants and young children who
accidentally touch or lick the lesion site. A bandage will protect the treated
area and avoid accidental transfer of ointment to the eyes or other areas.
Use the medication for the full time recommended by the healthcare
practitioner, even though symptoms may have improved.
Notify the healthcare practitioner if there is no improvement in symptoms
within 3 to 4 days after starting use of ALTABAX.
ALTABAX may cause reactions at the site of application of the ointment. …
Warnings & precautions
Do not take this medicine if: None.
In the event of sensitization or severe local irritation from
ALTABAX, usage should be discontinued, the ointment wiped off, and appropriate
alternative therapy for the infection instituted .
ALTABAX is not intended for ingestion or for oral, intranasal,
ophthalmic, or intravaginal use. ALTABAX has not been evaluated for use on
mucosal surfaces .
The use of antibiotics may promote the selection of
nonsusceptible organisms. Should superinfection occur during therapy,
appropriate measures should be taken.
Prescribing ALTABAX in the absence of a proven or strongly suspected
bacterial infection is unlikely to provide benefit to the patient and increases
the risk of the development of drug-resistant bacteria.
Retapamulin side effects
The safety profile of ALTABAX was assessed in 2,115 adult and
pediatric patients ≥9 months who used at least one dose from a 5-day, twice a
day regimen of retapamulin ointment. Control groups included 819 adult and
pediatric patients who used at least one dose of the active control (oral
cephalexin), 172 patients who used an active topical comparator (not available
in the US), and 71 patients who used placebo.
Adverse events rated by investigators as drug-related occurred in 5.5%
(116/2,115) of patients treated with retapamulin ointment, 6.6% (54/819) of
patients receiving cephalexin, and 2.8% (2/71) of patients receiving placebo.
The most common drug-related adverse events (≥1% of patients) were application
site irritation (1.4%) in the retapamulin group, diarrhea (1.7%) in the
cephalexin group, and application site pruritus (1.4%) and application site
paresthesia (1.4%) in the placebo group.
Because clinical studies are conducted under varying conditions, adverse
reaction rates observed in the clinical studies of a drug cannot be directly
compared to rates in the clinical studies of another drug and may not reflect
the rates observed in practice. The adverse reaction information from the
clinical studies does, however, provide a basis for identifying the adverse
events that appear to be related to drug use and for approximating rates. …
Drug interactions
Co-administration of oral ketoconazole 200 mg twice daily
increased retapamulin geometric mean AUC(0-24) and Cmax by 81% after topical application of retapamulin ointment,
1% on the abraded skin of healthy adult males. Due to low systemic exposure to
retapamulin following topical application in patients, dosage adjustments for
retapamulin are unnecessary when co-administered with CYP3A4 inhibitors, such as
ketoconazole. Based on in vitro P450 inhibition studies and the low systemic
exposure observed following topical application of ALTABAX, retapamulin is
unlikely to affect the metabolism of other P450 substrates.
The effect of concurrent application of ALTABAX and other topical products to
the same area of skin has not been studied.
About this medicine
ALTABAX contains retapamulin, a semisynthetic pleuromutilin antibiotic. The
chemical name of retapamulin is acetic acid, [[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]thio]-, (3aS,4R,5S,6S,8R,9R,9aR,10R)-6-ethenyldecahydro-5-hydroxy-4,6,9,10-tetramethyl-1-oxo-3a,9-propano-3aH-cyclopentacycloocten-8-yl ester. Retapamulin, a white to
pale-yellow crystalline solid, has a molecular formula of C30H47NO4S, and a
molecular weight of 517.78. The chemical structure is:
Each gram of ointment for dermatological use contains 10 mg of retapamulin in
white petrolatum.
How it works: ALTABAX is an antibacterial agent . In post-hoc analyses of manually over-read 12-lead ECGs from healthy subjects (N = 103), no significant effects on QT/QTc intervals were observed after topical application of retapamulin ointment on intact and abraded skin. Due to the low systemic exposure to retapamulin with topical application, QT prolongation in patients is unlikely .
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 9fae06b5-bbd5-400a-a7a6-3a4e238361f8. Read the full official label on DailyMed.